FLORHAM PARK, N.J., Oct. 10, 2017 -- Hisamitsu America, a division of Hisamitsu Pharmaceutical Co., Inc., and the manufacturers of the popular, unscented Salonpas® Lidocaine 4% Pain Relieving Patch, the top-selling product in the lidocaine segment, announce the Lidocaine Plus product line with the introduction of the Salonpas® Lidocaine Plus Pain Relieving Cream and the Salonpas® Lidocaine Plus Pain Relieving Liquid.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/153e6261-2eae-4aa2-89bd-9556ffbd0806
“The Lidocaine Plus products contain two powerful anesthetics including long-lasting 4% lidocaine which is the maximum strength available without a prescription and fast-acting 10% benzyl alcohol,” said John Incledon, President & CEO, Hisamitsu America. “The Salonpas Lidocaine Plus products desensitize aggravated nerves for temporary relief of back, neck, shoulder, knee and elbow pain.”
“I have been using the new Salonpas® Lidocaine Plus products to address knee and elbow pain after my rigorous work-outs and found that the cream and liquid worked effectively,” said award-winning journalist Dr. Bob Arnot, M.D., internal medicine, author of twelve books on nutrition and health, host of the Dr. Danger reality TV series, and previously Chief Medical Correspondent for NBC and CBS News, and Chief Foreign Correspondent for MSNBC and NBC. Dr. Arnot is also a Paddleboard World Championship award winner.
Salonpas Lidocaine Plus Pain Relieving Cream (MSRP: $12.99) provides non-greasy, fast-absorbing numbing relief. The Salonpas® Lidocaine Plus Pain Relieving Liquid (MSRP: $12.99) features a no-mess, roller ball applicator that keeps hands clean while providing long-lasting pain relief. All of the Salonpas lidocaine products, including the Lidocaine 4% Pain Relieving Patch, are unscented.
The new Salonpas® Lidocaine Plus Pain Relieving Cream and the Salonpas® Lidocaine Plus Pain Relieving Liquid are available at leading retailers nationwide.
Euromonitor International Limited reports that Salonpas® is world’s number one OTC topical analgesic patch brand. In October 2016, Hisamitsu America launched the Salonpas® Lidocaine 4% Pain Relieving Patch which has become the best-selling product in the lidocaine segment*. The company manufactures their own patches ensuring strict adherence to the highest quality standards. Salonpas® sells 13 patches every second with over 1 million sold daily in the United States.
About Hisamitsu America:
Hisamitsu America is the US division of Hisamitsu Pharmaceutical Co., Inc., founded in 1847, which has specialized in patch technology since the introduction of its Salonpas line of patches in 1934. Salonpas®, which gained early acceptance in Japan and now sells in over 50 countries, has pioneered the development of topical patches to relieve everyday aches and pains. Today, the Salonpas® Pain Relief Patch is the first and only FDA-approved OTC pain patch. For more information, visit www.salonpas.us.
*#1 in $ Sales for the Building Calendar Year 2017 ending 9/10/17 among Lidocaine ingredient products (Category: External Analgesics)
Media Contact: Nancy Thompson, Vorticom, Inc. 212.532.2208; [email protected]


Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 



